A Randomized Phase 2 Trial of Doxorubicin Plus Pemetrexed Followed by Docetaxel, Versus Doxorubicin Plus Cyclophosphamide Followed by Docetaxel, as Neoadjuvant Treatment for Early Breast Cancer. [STUDIO RANDOMIZZATO DI FASE II DI CONFRONTO TRA DOXORUBICINA + PEMETREXED SEGUITO DA DOCETAXEL VERSUS DOXORUBICINA + CICLOFOSFAMIDE SEGUITO DA DOCETAXEL, COME TRATTAMENTO NEOADIUVANTE DEL TUMORE DELLA MAMMELLA IN STADIO INIZIALE]

Trial Profile

A Randomized Phase 2 Trial of Doxorubicin Plus Pemetrexed Followed by Docetaxel, Versus Doxorubicin Plus Cyclophosphamide Followed by Docetaxel, as Neoadjuvant Treatment for Early Breast Cancer. [STUDIO RANDOMIZZATO DI FASE II DI CONFRONTO TRA DOXORUBICINA + PEMETREXED SEGUITO DA DOCETAXEL VERSUS DOXORUBICINA + CICLOFOSFAMIDE SEGUITO DA DOCETAXEL, COME TRATTAMENTO NEOADIUVANTE DEL TUMORE DELLA MAMMELLA IN STADIO INIZIALE]

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Dec 2012

At a glance

  • Drugs Cyclophosphamide; Docetaxel; Doxorubicin; Pemetrexed
  • Indications Early breast cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 05 Jun 2012 Results at 3 years presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
    • 04 Jun 2010 Analysis investigating the correlation between the CD24 ala/val polymorphism and the pathological complete response at the 46th Annual Meeting of the American Society of Clinical Oncology.
    • 31 May 2009 Results were presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top